KR20230005198A - 히알루로니다제 투여에 의한 안구 손상 감소 또는 억제 - Google Patents

히알루로니다제 투여에 의한 안구 손상 감소 또는 억제 Download PDF

Info

Publication number
KR20230005198A
KR20230005198A KR1020227038208A KR20227038208A KR20230005198A KR 20230005198 A KR20230005198 A KR 20230005198A KR 1020227038208 A KR1020227038208 A KR 1020227038208A KR 20227038208 A KR20227038208 A KR 20227038208A KR 20230005198 A KR20230005198 A KR 20230005198A
Authority
KR
South Korea
Prior art keywords
minutes
hyaluronidase
composition
eye
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227038208A
Other languages
English (en)
Korean (ko)
Inventor
스티브 옐린
Original Assignee
메드 프로그레스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메드 프로그레스, 엘엘씨 filed Critical 메드 프로그레스, 엘엘씨
Publication of KR20230005198A publication Critical patent/KR20230005198A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
KR1020227038208A 2020-04-02 2021-04-02 히알루로니다제 투여에 의한 안구 손상 감소 또는 억제 Pending KR20230005198A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063004444P 2020-04-02 2020-04-02
US63/004,444 2020-04-02
PCT/US2021/025668 WO2021203062A1 (en) 2020-04-02 2021-04-02 Reducing or inhibiting ocular damage by hyaluronidase administration

Publications (1)

Publication Number Publication Date
KR20230005198A true KR20230005198A (ko) 2023-01-09

Family

ID=77921064

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227038208A Pending KR20230005198A (ko) 2020-04-02 2021-04-02 히알루로니다제 투여에 의한 안구 손상 감소 또는 억제

Country Status (11)

Country Link
US (1) US11878051B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125928A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023521059A (cg-RX-API-DMAC7.html)
KR (1) KR20230005198A (cg-RX-API-DMAC7.html)
CN (1) CN115697348A (cg-RX-API-DMAC7.html)
AU (1) AU2021248653B2 (cg-RX-API-DMAC7.html)
CA (1) CA3174498A1 (cg-RX-API-DMAC7.html)
IL (1) IL296979A (cg-RX-API-DMAC7.html)
MX (1) MX2022012426A (cg-RX-API-DMAC7.html)
WO (1) WO2021203062A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211833B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024003755A (es) * 2021-09-25 2024-04-15 Med Progress Llc Reduccion o inhibicion del da?o tisular mediante la administracion de hialuronidasa.
KR102922198B1 (ko) * 2022-04-25 2026-02-03 주식회사 메디팹 조직 수복용 생체재료의 분해 또는 교정용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
KR100566451B1 (ko) * 1997-05-22 2006-03-31 이스타 파마슈티칼스, 인크. 안질환 치료에서 초자체액의 액화를 위한 안과용 제제의 제조에 있어서의 히알루로니다제의 용도
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US20090311237A1 (en) * 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
US20120101033A1 (en) 2010-10-05 2012-04-26 Shantha Totada R Retinitis pigmentosa treatment
US11076992B2 (en) 2019-04-19 2021-08-03 Elt Sight, Inc. Methods of transverse placement in ELT

Also Published As

Publication number Publication date
ZA202211833B (en) 2023-04-26
WO2021203062A1 (en) 2021-10-07
JP2026065067A (ja) 2026-04-14
AU2021248653B2 (en) 2024-05-02
MX2022012426A (es) 2023-01-11
CN115697348A (zh) 2023-02-03
CA3174498A1 (en) 2021-10-07
EP4125928A1 (en) 2023-02-08
US20210308234A1 (en) 2021-10-07
IL296979A (en) 2022-12-01
US11878051B2 (en) 2024-01-23
EP4125928A4 (en) 2024-06-12
JP2023521059A (ja) 2023-05-23
AU2021248653A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
Kitazawa et al. Trabeculectomy with mitomycin: a comparative study with fluorouracil
Chalam et al. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma
JP2026065067A (ja) ヒアルロニダーゼの投与による目の損傷の低減又は抑制
Anderson et al. Comparison of preservative-free bupivacaine vs lidocaine for intracameral anesthesia: a randomized clinical trial and in vitro analysis
US20150174216A1 (en) Methods for Treating Adhesive Capsulitis
Karp et al. Intracameral anesthesia: a report by the American Academy of Ophthalmology
TW202135789A (zh) 糖尿病黃斑水腫及受損之視覺敏銳度的治療
US20060166956A1 (en) Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
CN108883081A (zh) 蛋白酶体抑制剂治疗眼部疾病的用途
CN101972224A (zh) 一种眼用原位凝胶
Peyman et al. Combination therapies in ophthalmology: implications for intravitreal delivery
US11890331B2 (en) Reducing or inhibiting ocular damage by hyaluronidase administration
US20240123041A1 (en) Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration
Sridharrao et al. Efficacy and safety of apraclonidine in patients undergoing anterior segment laser surgery.
US20080138350A1 (en) Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery
Duan et al. Preliminary study of a controllable device for subtenon drug infusion in a rabbit model
Yeniad et al. Assessment of anterior chamber inflammation after intravitreal bevacizumab injection in different ocular exudative diseases
KR20240065265A (ko) 히알루로니다제 투여를 이용한 조직 손상의 감소 또는 억제
US20060034890A1 (en) Device for ocular delivery of active principles by the transpalpebral route
Soekamto et al. Intravitreal Injections for Pediatric Retinal Diseases
KR20230007245A (ko) 이미다졸 유도체를 포함하는 안질환의 예방 또는 치료용 조성물 및 이의 용도
Jeevakanthi et al. An Unusual Case of Fusarium Endophthalmitis: The Importance of Early Diagnosis and Treatment
CN119215007A (zh) 一种冻干粉形式的抗病毒多肽抑菌剂
TW202432158A (zh) 含鳶尾素成分(Irigenin)之鳶尾科植物天然萃取物用於製備保健眼睛之眼用組合物的用途
CN119192391A (zh) 一种融合多肽aj007及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902